At a glance

Underpinning these changes, we are committed to engage and confront some of the biggest public health challenges facing the US.

Over the last two years we have played a key role to develop treatments and vaccines against COVID. Through a partnership with Vir Biotechnology we have developed, and contracted, with the US Government for approximately $1 billion for our monoclonal antibody, Sotrovimab, which demonstrated it can reduce hospitalization and risk of death by 79% in adults with mild-to-moderate COVID-19 who are at high risk of progression to severe disease.

This is an urgent threat to public health. By undermining the effectiveness of antibiotics, it currently contributes to 700,000 deaths every year globally, a figure that is expected to increase significantly unless action is taken. We’re focusing on organisms with the highest risk of developing AMR as characterized by the Centers for Disease Control and Prevention (CDC) and World Health Organization (WHO).

GSK is committed to responsible pricing as demonstrated through our actions and track record over time. In fact, our average net price for GSK and ViiV products (price after discounts, rebates or other allowances) in the US decreased about 1.9% on average annually over the past five years

During 2021, GSK provided prescribed vaccines and medicines to more than 87,000 low-income uninsured, underinsured, and Medicare Part D patients through GSK and ViiV Healthcare’s Patient Assistance Programs Foundation

• Therapeutic areas in the Patient Assistance Programs include respiratory, immunology, oncology, vaccines and HIV. Significant product additions in 2021 include Cabenuva and Apretude.
• Charitable donations through the Patient Assistance Programs Foundation are available in all 50 States, Washington, DC, Puerto Rico, and the US Virgin Islands

The Wholesale Acquisition Cost (WAC) -- which is the manufacturer’s list price for a drug or biological to wholesalers or direct purchasers -- in the US for GSK contributed products during 2021 was $494 million and for ViiV products was $96 million. The total WAC Value was $590 million.

To raise awareness of the serious nature of shingles – which will impact 1 in 3 adults – GSK and the International Federation on Ageing (IFA) collaborated in 2022 to launch the first ever Shingles Awareness Week. The goal of Shingles Awareness Week is to grow the understanding of the impact of the virus and to dispel common misconceptions regarding the risks of infection.